


Pipeline of Diverse Compound/Indications in Airfinity Database by Viral Family & Phase of Development* (n=687)

The majority (n=387; 56.3%) of 687 diverse compound/indications for priority viruses in November 2023 are preclinical with the majority of those targeting SARS-CoV-2 (n=239/387; 61.8%).

The majority (56.3%) of the 687 diverse compound/indications for the 12 priority viral families of pandemic potential are in preclinical development. This is followed by Phase 2 (12.2%), Phase 3 (10.3%), Phase 1 (6.8%), Phase 4 (4.5%), and Approved (9.75%). *Peribunyaviridae* is currently the only priority viral family adjudged to have no compounds in development in November 2023.

LIMITATIONS:

- Compound/Indications selected based on association with a viral disease irrespective of compound's mechanism of action.
- Compounds that have had no activity in the past 12 months are marked as inactive and excluded from this analysis.
- Compound/Indications list is being updated frequently.
- Pipeline shows those in preclinical/clinical development as well as approved by a global regulatory authority (stringent or other national authority).
- Preclinical compounds must have shown antiviral activity via *in vitro* or *in vivo* animal models in peer-reviewed publications or preprints.



*As of November 16, 2023



INTREPID ALLIANCE
INTERNATIONAL READINESS FOR PREVENTING INFECTIOUS VIRAL DISEASE

Interested
in engaging
with us?

For more information, contact
nina@intrepidalliance.org.

 intrepidalliance.org

 linkedin.com/company/intrepid-alliance